Lutetium-177 Market Size, Share & Industry Analysis, By Drug (LUTATHERA {lutetium Lu 177 dotatate}, PLUVICTO {lutetium Lu 177 vipivotide tetraxetan}, and Others) By Age Group (Adults and Pediatrics), By Application (Neuroendocrine Tumor, Prostate Cancer, and Others) By End-User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

Last Updated: January 19, 2026 | Format: PDF | Report ID: FBI112740

To get information on various segments, share your queries with us

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2021–2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 19.95% from 2026-2034
Unit	Value (USD Billion)
Segmentation	By Drug LUTATHERA (lutetium Lu 177 dotatate) PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) Others
	By Age Group Adults Pediatrics
	By Application Neuroendocrine Tumor Prostate Cancer Others
	By End-User Hospitals Specialty Clinics Others
	By Region North America (By Drug, Age Group, Application, End-User, and Country) U.S. Canada Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region) Germany U.K. France Spain Italy Rest of Europe Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region) China Japan India Australia Rest of Asia Pacific Rest of the World ( By Drug, Age Group, Application, and End-User)